Hypoglycaemia (low blood sugar) is uncommon with GLP-1 receptor agonists when used alone, as they work in a glucose-dependent manner
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, not yet licensed by the MHRA or EMA, with Phase 2 data showing substantial weight reduction over 48 weeks
Severe side effects that warrant contacting a healthcare provider include: Severe abdominal pain : This could be a sign of pancreatitis or gallbladder issues, which require immediate evaluation
Recent FDA approvals and indications for products containing semaglutide include the reduction of cardiovascular risk in patients with type 2 diabetes and body weight reduction for obesity
Membership includes ongoing communication with licensed providers, nurse-led coaching, and an insurance concierge for cost support
For patients seeking to purchase Retatrutide, understanding your options, the ordering process, and safety considerations is essential for making informed decisions about your treatment journey